SAMSUNG BIOLOGICS CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 770,000 KRW | -1.28% |
|
-1.41% | +1.32% |
| Apr. 25 | Samsung Bioepis Granted Approval to Market Autoimmune Treatment in Europe | MT |
| Apr. 25 | Samsung Biologics Posts Higher Q1 Profit, Sales | MT |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 54,652,290 | 59,746,995 | 58,433,854 | 54,092,240 | 54,803,980 | - | - |
| Enterprise Value (EV) 2 | 55,086 | 59,668 | 57,746 | 53,840 | 52,719 | 51,843 | 50,780 |
| P/E ratio | - | 152 x | 71.8 x | 63.1 x | 56.3 x | 47.9 x | 39.9 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | 46.9 x | 38.1 x | 19.5 x | 14.6 x | 12.9 x | 11.2 x | 9.8 x |
| EV / Revenue | 47.3 x | 38.1 x | 19.2 x | 14.6 x | 12.4 x | 10.5 x | 9.08 x |
| EV / EBITDA | 126 x | 85.4 x | 44.7 x | 33.6 x | 29.4 x | 25.5 x | 21.9 x |
| EV / FCF | 882 x | 1,234 x | -15,229 x | 80.2 x | 54.1 x | 53.9 x | 49.3 x |
| FCF Yield | 0.11% | 0.08% | -0.01% | 1.25% | 1.85% | 1.85% | 2.03% |
| Price to Book | 11.9 x | 12 x | 6.38 x | 5.5 x | 5.07 x | 4.6 x | 4.13 x |
| Nbr of stocks (in thousands) | 66,165 | 66,165 | 71,174 | 71,174 | 71,174 | - | - |
| Reference price 3 | 826,000 | 903,000 | 821,000 | 760,000 | 770,000 | 770,000 | 770,000 |
| Announcement Date | 1/26/21 | 1/24/22 | 1/27/23 | 1/24/24 | - | - | - |
1KRW in Million2KRW in Billions3KRW
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 1,165 | 1,568 | 3,001 | 3,695 | 4,263 | 4,915 | 5,590 |
| EBITDA 1 | 436.5 | 699.1 | 1,292 | 1,603 | 1,793 | 2,037 | 2,321 |
| EBIT 1 | 292.8 | 537.3 | 983.6 | 1,114 | 1,254 | 1,499 | 1,763 |
| Operating Margin | 25.14% | 34.27% | 32.77% | 30.14% | 29.42% | 30.5% | 31.54% |
| Earnings before Tax (EBT) 1 | - | 561.3 | 1,009 | 1,120 | 1,248 | 1,495 | 1,798 |
| Net income 1 | - | 393.6 | 798.1 | 857.7 | 973.6 | 1,176 | 1,373 |
| Net margin | - | 25.1% | 26.59% | 23.21% | 22.84% | 23.92% | 24.55% |
| EPS 2 | - | 5,949 | 11,432 | 12,051 | 13,679 | 16,084 | 19,288 |
| Free Cash Flow 3 | 62,425 | 48,343 | -3,792 | 671,158 | 974,040 | 961,380 | 1,029,170 |
| FCF margin | 5,359.41% | 3,083.07% | -126.34% | 18,165.97% | 22,847.59% | 19,560.25% | 18,410.56% |
| FCF Conversion (EBITDA) | 14,302.14% | 6,915.01% | - | 41,856.8% | 54,333.77% | 47,203.92% | 44,347.72% |
| FCF Conversion (Net income) | - | 12,282.53% | - | 78,251.71% | 100,048.62% | 81,776.64% | 74,977.04% |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Announcement Date | 1/26/21 | 1/24/22 | 1/27/23 | 1/24/24 | - | - | - |
1KRW in Billions2KRW3KRW in Million
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 450.7 | 444.3 | 511.3 | 651.4 | 873 | 965.5 | 720.9 | 866.2 | 1,034 | 1,074 | 946.9 | 986.1 | 1,041 | 1,260 | 1,212 |
| EBITDA 1 | 208.2 | 171 | 215.9 | 258.6 | 409.4 | 405.2 | 292.4 | 362.1 | 457.9 | - | 353 | 457.2 | 496.5 | 547.9 | - |
| EBIT 1 | 167.4 | 128.8 | 176.4 | 169.7 | 324.7 | 312.8 | 191.7 | 253.4 | 318.5 | 350 | 221.3 | 298.7 | 314 | 400.2 | 410.9 |
| Operating Margin | 37.14% | 29% | 34.5% | 26.05% | 37.2% | 32.4% | 26.6% | 29.26% | 30.81% | 32.6% | 23.37% | 30.3% | 30.18% | 31.76% | 33.9% |
| Earnings before Tax (EBT) 1 | - | 109.2 | 198.5 | 214.5 | 198.4 | 397.6 | 196.6 | 251.3 | 316.3 | 355.7 | 240.1 | 333.9 | 299.5 | 398.8 | 407.9 |
| Net income 1 | 131.8 | 79.32 | 146.9 | 152 | 129.2 | 369.9 | 141.8 | 184.9 | 240.4 | 290.7 | 179.4 | 233.6 | 240 | 327.5 | 310 |
| Net margin | 29.24% | 17.85% | 28.74% | 23.34% | 14.79% | 38.31% | 19.66% | 21.34% | 23.25% | 27.08% | 18.94% | 23.69% | 23.06% | 25.99% | 25.58% |
| EPS 2 | - | - | - | - | 1,815 | 5,258 | 1,992 | 2,597 | 3,376 | 4,084 | 2,749 | 3,105 | 3,315 | 4,178 | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 10/26/21 | 1/24/22 | 4/27/22 | 7/27/22 | 10/26/22 | 1/27/23 | 4/24/23 | 7/26/23 | 10/25/23 | 1/24/24 | 4/24/24 | - | - | - | - |
1KRW in Billions2KRW
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | 434 | - | - | - | - | - | - |
| Net Cash position 1 | - | 78.7 | 688 | 253 | 2,085 | 2,961 | 4,024 |
| Leverage (Debt/EBITDA) | 0.9932 x | - | - | - | - | - | - |
| Free Cash Flow 2 | 62,425 | 48,343 | -3,792 | 671,158 | 974,040 | 961,380 | 1,029,170 |
| ROE (net income / shareholders' equity) | 5.38% | 8.21% | 11.4% | 9.12% | 9.63% | 10.3% | 11.1% |
| ROA (Net income/ Total Assets) | 3.91% | 5.47% | 6.5% | 5.26% | 5.81% | 6.46% | 7.18% |
| Assets 1 | - | 7,197 | 12,277 | 16,314 | 16,744 | 18,185 | 19,111 |
| Book Value Per Share 3 | 69,505 | 75,434 | 128,700 | 138,119 | 151,823 | 167,419 | 186,428 |
| Cash Flow per Share 3 | - | 11,233 | 13,652 | 23,411 | 21,419 | 23,299 | 27,328 |
| Capex 1 | 140 | 406 | 957 | 995 | 1,077 | 940 | 793 |
| Capex / Sales | 11.99% | 25.91% | 31.88% | 26.93% | 25.26% | 19.13% | 14.19% |
| Announcement Date | 1/26/21 | 1/24/22 | 1/27/23 | 1/24/24 | - | - | - |
1KRW in Billions2KRW in Million3KRW
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
770,000
KRW
Average target price
1,032,273
KRW
Spread / Average Target
+34.06%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +1.32% | 39.82B | |
| -4.66% | 86.13B | |
| -19.27% | 30.42B | |
| +57.86% | 25.23B | |
| -16.09% | 15.35B | |
| -9.14% | 11.95B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| +5.24% | 8.71B | |
| -8.42% | 8.12B |
- Stock Market
- Equities
- A207940 Stock
- Financials Samsung Biologics Co.,Ltd.
